中国行为医学科学
中國行為醫學科學
중국행위의학과학
2008年
3期
234-236
,共3页
强迫症%难治性%喹硫平%疗效%认知功能
彊迫癥%難治性%喹硫平%療效%認知功能
강박증%난치성%규류평%료효%인지공능
Obsessive-compulsive disorder%Refractory-treatment%Quetiapine%Effect%Cognitive function
目的 观察喹硫平合并5-羟色胺再摄取抑制剂治疗难治性强迫症的疗效及对认知功能的影响.方法 58名难治性强迫症患者,随机分为喹硫平合并治疗组(n=29)和安慰剂合并治疗组(n=29).在基线和治疗8周结束时进行Yale-Brown量表和认知功能评定,认知功能评定包括威斯康星卡片分类测验,Stroop测验,持续操作试验,韦氏记忆量表,以评估患者的注意、记忆和执行功能.比较2组治疗前后Yale-Brown量表和认知功能评分.结果 喹硫平合并治疗组和安慰剂组治疗前Yale-Brown量表总分分别为(28.5±4.4)分,(26.3±6.5)分;治疗后分别为(18.5±6.4)分,(25.7±5.4)分,差异有显著性(P=0.01).治疗前后威斯康星卡片分类测验中维持不能数增加,治疗前分别为(1.2±1.1)分,(1.3±1.4)分;治疗后分别为(1.6±1.0)分,(1.5±1.2)分,差异有显著性(P=0.03),其余认知功能测验指标治疗前后差异无显著性.结论 喹硫平合并治疗对难治性强迫症有效,对认知功能无明显影响.
目的 觀察喹硫平閤併5-羥色胺再攝取抑製劑治療難治性彊迫癥的療效及對認知功能的影響.方法 58名難治性彊迫癥患者,隨機分為喹硫平閤併治療組(n=29)和安慰劑閤併治療組(n=29).在基線和治療8週結束時進行Yale-Brown量錶和認知功能評定,認知功能評定包括威斯康星卡片分類測驗,Stroop測驗,持續操作試驗,韋氏記憶量錶,以評估患者的註意、記憶和執行功能.比較2組治療前後Yale-Brown量錶和認知功能評分.結果 喹硫平閤併治療組和安慰劑組治療前Yale-Brown量錶總分分彆為(28.5±4.4)分,(26.3±6.5)分;治療後分彆為(18.5±6.4)分,(25.7±5.4)分,差異有顯著性(P=0.01).治療前後威斯康星卡片分類測驗中維持不能數增加,治療前分彆為(1.2±1.1)分,(1.3±1.4)分;治療後分彆為(1.6±1.0)分,(1.5±1.2)分,差異有顯著性(P=0.03),其餘認知功能測驗指標治療前後差異無顯著性.結論 喹硫平閤併治療對難治性彊迫癥有效,對認知功能無明顯影響.
목적 관찰규류평합병5-간색알재섭취억제제치료난치성강박증적료효급대인지공능적영향.방법 58명난치성강박증환자,수궤분위규류평합병치료조(n=29)화안위제합병치료조(n=29).재기선화치료8주결속시진행Yale-Brown량표화인지공능평정,인지공능평정포괄위사강성잡편분류측험,Stroop측험,지속조작시험,위씨기억량표,이평고환자적주의、기억화집행공능.비교2조치료전후Yale-Brown량표화인지공능평분.결과 규류평합병치료조화안위제조치료전Yale-Brown량표총분분별위(28.5±4.4)분,(26.3±6.5)분;치료후분별위(18.5±6.4)분,(25.7±5.4)분,차이유현저성(P=0.01).치료전후위사강성잡편분류측험중유지불능수증가,치료전분별위(1.2±1.1)분,(1.3±1.4)분;치료후분별위(1.6±1.0)분,(1.5±1.2)분,차이유현저성(P=0.03),기여인지공능측험지표치료전후차이무현저성.결론 규류평합병치료대난치성강박증유효,대인지공능무명현영향.
Objective To investigate the efficacy and effects on cognitive functioning of antipsychotic addition to serotonin reuptake inhibitors in patients with treatment-refractory obsessive-compulsive disorder. Methods 58 therapy-resistant OCD patients were randomly grouped and receipt 8-week quetiapine-augmentation treatment or placebo respectively. At baseline and post-treatment, in order to evaluate symptom, executive functions, attention and memory, all patients were measured with Yale-Brown Obsessive-Compulsive Scale and cognitive functioning test, which included Wisconsin Card Sorting Test, Stroop Color Word Test,Continuous Performance Test and Memory Scale. Results Comparing quetiapine-augmentation group and placebo, there was significant difference of Y-BOCS total score between baseline and post-treatment (baseline:28.5±4.4,26.3±6.5,post-treatment:18.5±6.4,25.7±5.4, respectively,P=0.01). There was no major effects on cognitive functioning, apart from a failure to maintain set on the WCST (baseline:1.2±1.1,1.3±1.4,post-treatment:1.6±1.0,1.5±1.2,respectively,P=0.03).Conclusion It was effective of quetiapine-augmentation treatment on refractory OCD. There was no major effects on cognitive functioning of quetiapine-augmentation treatment.
